GENB Overview

Generate Biomedicines, Inc. is a clinical-stage generative biology company focusing on the Artificial intelligence (AI) revolution in biotechnology and drug design and development. The Company is engaged in the field of generative biology using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its Generate Platform integrates generative and predictive models that learn design principles from proprietary data and graph neural networks, among other architectures. Its lead product candidate, GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma. Its other product candidates include GB-4362, a systemically administered monoclonal antibody designed to neutralize free monomethyl auristatin E (MMAE) as an adjunctive therapy to antibody-drug conjugate (ADC) molecules with an MMAE payload, as well as GB-5267, an armored, MUC16-directed CAR-T cell therapy candidate.

Wall Street analysts forecast GENB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GENB is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Generate Biomedicines Inc revenue for the last quarter amounts to NaN USD, decreased

Generate Biomedicines Inc. EPS for the last quarter amounts to USD, decreased

Generate Biomedicines Inc (GENB) has 312 emplpoyees as of March 25 2026.

Today GENB has the market capitalization of 1.60B USD.